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Background: Vascular endothelial growth factor (VEGF) may play a role on the allograft remodelling following cardiac
transplantation (CTx). We measured the circulating levels of VEGF-A165 concomitantly with the proinflammatory
(Interleukin-8; IL-8), anti-inflammatory (IL-1 receptor antagonist; IL-1RA) and their release from neutrophils of CTx
recipients.
Methods: Eighteen CTx recipients aged 49.6 ± 3.1 years, being transplanted for 145 ± 20 months were age-matched to
35 healthy control (HC) subjects. Concomitantly to plasma assessment, circulating neutrophils were isolated, purified
and stimulated by vehicle (PBS), N-formyl-Met-Leu-Phe (fMLP, 10−7 M), bacterial lipopolysaccharide (LPS, 1 μg/mL), or
tumour necrosis factor alpha (TNF-α, 10 ng/mL).
Results: Compared with HC, CTx recipients exhibited a decrease (−80%) in plasmatic levels of VEGF-A165 (225 ± 42 (HC)
vs 44 ± 10 pg/mL (CTx); (p < 0.001). There were no differences in the levels of IL-8 and IL-1RA. Under basal or stimulated
conditions, neutrophils from CTx patients exhibited a marked decrease ranging from −30 to −88% on their capacity to
release VEGF-A165, IL-8 and IL-1RA upon stimulation.
Conclusions: Long-term CTx recipients exhibit a marked reduction in the circulating levels of VEGF-A165, as well as
neutrophil-mediated release of VEGF-A165, IL-1RA and IL-8 compared to healthy volunteers. The mechanisms and
physiological impacts of these findings deserve additional investigations.
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De novo [1] and long-term cardiac [2] transplantation
(CTx) are characterised by an increase in the circulat-
ing markers of subclinical inflammation and oxidative
stress. Selected biomarkers related to these processes
remain elevated more than 8 years following cardiac
transplantation [2]. Coronary allograft vasculopathy
(CAV) exhibits distinct histologic and pathophysiologic
features [3]. Also a chronic state of inflammation likely
contributes to CAV but also to the long-term vascular
complications following solid organ and cardiac trans-
plantation [4,5].* Correspondence: martin.sirois@icm-mhi.org; m_white@icm-mhi.com
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unless otherwise stated.Although multiple growth factors induce the prolif-
eration and migration of endothelial cells (EC), vascu-
lar endothelial growth factor (VEGF) is the only
growth factor capable to promote protein extravasation
which is linked to its angiogenic properties [6-8].
There are five different VEGF-A isoforms, of various
members of amino acids, termed as VEGF-A206, 189,
165, 145 and 121, which are produced from a single gene
by alternative splicing. The VEGF family also includes
five different analogs: placental growth factor (PlGF-1
and −2), VEGF-B, VEGF-C, VEGF-D, and a viral homo-
log, VEGF-E [6-9]. In addition, neuropilin-1 (NRP-1), a
transmembrane receptor, acts as a coreceptor, com-
plexing with VEGF receptors (VEGFR-1 and VEGFR-2)
[10-13]. NRP-1 specifically enhances the binding of
VEGF-A165 to VEGFR-2 and potentiates variousThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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VEGF analog capable to promote biological activities is
mainly driven by VEGF-A165 isoform. Chronic cardiac
hypoxia likely contributes to molecular remodeling in
the transplanted human hearts [14-16]. In fact, cardiac
VEGF-A isoforms increase concomitantly with the pres-
ence of fibrin depositions [17] and endomyocardial fibrosis
following CTx [16]. Also more recent investigations re-
ported an increase in circulating VEGF-A165 and VEGF-C
in patients with CAV. However data were not compared
with healthy control subjects [18].
The neutrophil plays a significant role on vascular pro-
inflammatory responses [19,20]. Data generated from
model systems showed that the neutrophil mediated
smooth muscle cell loss precedes CAV [21]. Neutrophils
can promote the release of various interleukins such as
IL-1, IL-6 and IL-8, which may play a significant role on
the vascular inflammatory microenvironment and conse-
quently on the long-term complications following organ
transplantation [22-24]. Although VEGF-A mRNA and
protein isoforms have been measured in cardiac tissue fol-
lowing CTx [16,17], the assessment of circulating levels of
VEGF-A165, but also levels of pro- and anti-inflammatory
cytokines concomitantly with the evaluation of neutrophil
mediated inflammatory response have not been investi-
gated in stable long-term cardiac transplant recipients.
The primary objective of this investigation was to assess
the circulating levels of VEGF-A165, IL-8 and IL-1RA con-
comitantly with the study of basal and stimulated neutro-
phil’s proinflammatory response in stable long-term CTx
recipients. The secondary objective of this study was to ex-




Eighteen CTx recipients and 35 age-matched healthy con-
trol (HC) subjects were recruited. Patients were eligible if
they were clinically stable and received stable doses of im-
munosuppressive drugs for at least 4 weeks prior to enrol-
ment in the study. The most significant exclusion criteria
included recent cardiac rejection, active infection and any
clinically significant inflammatory condition such as arth-
ritis or recent surgery. In addition, patients with significant
anemia (hemoglobin ≤90 g/L) poorly controlled diabetes
mellitus (glycated hemoglobin ≥ 10%) or systemic hyperten-
sion, active cancer (other than skin cancer), and severe
renal failure (creatinine clearance less than 15 ml/min/m2)
were excluded. Patients were recruited regardless of the
presence or absence of cardiac allograft vasculopathy
(CAV). Patients had to present stable or no symptoms for
at least 3 months, and CAV was diagnosed by coronary
angiography. The HC group had to be free from any med-
ical condition or medication for at least 10 days prior to theexperiments. The study was conducted in accordance with
the Declaration of Helsinki and approved by the Montreal
Heart Institute’s ethical committee (Montreal, QC, Canada;
ethics No. ICM #01-406 and No. ICM #12-1374). All HC
and CTx provided written informed consent to the experi-
mental protocol before participating in the study.
Plasma biomarkers
Venous blood samples from both HC and CTx patients
were collected in the morning using the anticoagulant
Citrate Dextrose Solution USP (ACD) Formula A. Two
milliliters of plasma were centrifuged (11000 g, 2 min,
4°C) to obtain platelet-free plasma [25] and the samples
were immediately frozen at −80°C. Plasma levels of
VEGF-A165 (with no-cross reactivity for other native
VEGF-A isoforms or VEGF analogs), IL-1RA and IL-8
were further analyzed by ELISA using the R&D Systems
Quantikine kits (DVE00, DRA00B and HS800 respect-
ively; Minneapolis, MN, USA).
Neutrophil isolation and purification
One hundred mL of venous blood was drawn in accord-
ance with the guidelines of the Montreal Heart Institute’s
ethical committee. Neutrophils were isolated by using
Ficoll-Hypaque gradient and re-suspended in RPMI
medium (Lonza, Basel, Switzerland) supplemented with
25 mM Hepes (N-2-hydroxyethylpiperazine-N’-2-ethane-
sulfonic acid) and 1% penicillin/streptomycin as previously
described [26,27]. Contamination of isolated neutrophil
suspension with peripheral blood mononuclear cells was
less than 0.1% as determined by morphological analysis and
flow cytometry, and viability was found to be >98%, as
assessed by Trypan blue dye exclusion assay.
Neutrophil stimulation and treatments
Purified neutrophils (5×106/mL, 500 μL) were incubated
in RPMI-1640 solution (Gibco, Carlsbad, CA) supple-
mented with 5% fetal bovine serum (PAA Laboratories,
Etobicoke, ON), 1% penicillin/streptomycin/GlutaMAX
(P/S) (Gibco) and 25 mM HEPES (Sigma, Oakville, ON),
and termed RPMI (for complete RPMI-1640 solution).
Neutrophils were then stimulated for 2 and 24 hours
with control vehicle (PBS), N-Formyl-Met-Leu-Phe
(fMLP; 10-7 M) (Sigma, Oakville, ON), bacterial lipo-
polysaccharide (LPS; Escherichia coli 0111:B4; 1 μg/mL)
(Sigma, Oakville, ON) or tumor necrosis factor-α (TNF-
α; 10 ng/mL) (Peprotech, Rocky Hill, NJ) at 37°C, 5%
CO2. Upon neutrophil stimulation, cells were centrifuged
at 900 g for 7 minutes and supernatants stored at −80°C
for future quantifications by ELISA of VEGF-A165, IL-1RA
and IL-8 (R&D Systems). The selected aforementioned ag-
onists (i.e. fMLP, LPS or TNF-α) were used because of
their capacity to promote VEGF-A165, IL-1RA and IL-8 re-
lease by the neutrophils [28-31].
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All results were expressed as mean ± SEM statistical com-
parisons were made by a one-way analysis of variance
(ANOVA), followed by a Bonferroni t-test. Software used
was StatView 5.0 and GraphPad Prism5.0. Differences
were considered significant at p values ≤ 0.05.
Results
The clinical characteristics of the study population are
presented in Table 1. A total of 53 subjects were enrolled
including 18 cardiac transplant recipients (CTx) and 35
age-matched healthy controls (HC). All CTx were maleTable 1 Clinical characteristics of the study population




Age (years) 49.6 ± 3.1 49.3 ± 1.6
Male 18 (100%) 16 (46%)
Body mass index (kg/m2) 26.5 ± 0.8



















Calcium channel blockers 14 (78%)
Immunosuppressive
treatments; n (%)





Yes (%) 4 (22%)
No (%) 14 (78%)
ACEi: Angiotensin-converting enzyme inhibitor; ARBs: angiotensin II receptor
blockers; CAD: Coronary artery disease, CAV: Cardiac allograft vasculopathy,
MMF: Mycophenolate mofetil; MPA: Mycophenolate acid; NYHA: New York
heart association. variables are expressed as mean ± SEM and percentages.and the CTx patients were studied 145 ± 20 months fol-
lowing transplantation. More than 60% of our trans-
planted studied patients exhibited treated hypertension
(n = 12) and dyslipidemia (n = 11) and 39% of them (n = 7)
exhibited CAV. Mean creatinine clearance measured by
the MDRD formula was 67.4 ± 19.7 ml/min/m2 (median
66.8; 25.5 – 107). Angiography was used in all patients to
assess for CAV. All patients with CAV exhibited CAV1.
By design, all the patients received stable immunosuppres-
sive drug doses for at least 4 weeks before their enrolment
in the study. The majority of patients received the com-
bination of tacrolimus (TAC) and mycophenolate mofetil/
enteric-coated mycophenolic acid (MMF/EC-MPA).
Biomarkers
Plasma levels of VEGF-A165, IL-1RA and IL-8 are pre-
sented in Figure 1. Compared with the healthy control
subjects, CTx recipients exhibited an 80% decrease in cir-
culating levels of VEGF-A165 (225 ± 42 (HC) vs 44 ±
10 pg/mL (CTx); p < 0.001). In contrast there were no sig-
nificant differences in the circulating levels of the anti-
inflammatory cytokine IL-1RA (205 ± 16 (HC) vs 243 ±
45 pg/mL (CTx)) and the proinflammatory cytokine IL-8
(7.90 ± 1.05 (HC) vs 4.62 ± 0.80 pg/mL (CTx)) between
both groups. There were no significant differences be-
tween patients with or without CAV (Table 2).
Neutrophil responses
There was a marked reduction in the capacity of neu-
trophils from CTx patients to promote the release of all
3 cytokines either under PBS basal condition or upon
stimulation with proinflammatory mediators (fMLP;
10−7 M, LPS; 1 μg/mL and TNF-α; 10 ng/mL) (Figure 2).
The quantification of VEGF-A165 and IL-1RA proteins was
performed after 2 hours post-stimulation with the afore-
mentioned proinflammatory agonists, whereas, the quanti-
fication of IL-8 protein was assessed after 24 hours of
treatment. All 3 agonists (fMLP, LPS and TNF-α) were
nearly equivalent to promote VEGF-A165 release compared
with PBS-treated neutrophils, ranging from 4.6 to 7.0-fold
increase in HC. In neutrophils from CTx patients, we ob-
served a similar pattern in the capacity of the agonists to
increase VEGF-A165 release (increase ranging from 3.8 to
5.0-fold) as compared to PBS-treated neutrophils. Never-
theless, the basal level of VEGF released by the neutrophils
from CTx patients was reduced by 36% as compared to HC
neutrophils. In HC, IL-1RA increased by 2.2- to 2.8-fold in
response to LPS and TNF-α respectively as compared to
PBS. In contrast CTx patients yielded a significantly lesser
increase in IL-1RA (1.5- and 2.3-fold by LPS and TNF-α
respectively).
The release of IL-8 was increased in response to 3 ago-
nists in HC. In contrast CTx patients exhibited a marked
decrease in IL-8 release in response to LPS and TNF-α
Figure 1 Plasma level of vascular endothelial growth factor (VEGF-A165), Interleukin-1 receptor antagonist (IL-1RA), and Interleukin-8 (IL-8). Data
are presented as mean ± SEM. ***p < 0.001 as compared to plasma level between healthy controls (HC) and cardiac transplant recipient (CTx).
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patients yielded an 88% decrease in their capacity to
release IL-8 under LPS stimulation (powerful proinflam-
matory mediator), whereas this reduction was less
significant in response to weaker proinflammatory medi-
ators (fMLP and TNF-α (Figure 2). There were no sig-
nificant differences in any of the study parameters in
patients with CAV (Table 2).Table 2 Circulating biomarkers and neutrophils
stimulation profiles for patients with and without
coronary allograph vasculopathy (CAV)
Parameters CAV (n = 7) No CAV (n = 11)
Biomarkers
VEGF-A165 63.3 ± 27.8 48.4 ± 15.1
IL-8 6.20 ± 1.59 3.61 ± 0.74
IL-RA 331 ± 99 187 ± 30
Neutrophils/Factors
VEGF release
PBS 10.5 ± 2.8 11.7 ± 1.9
fMLP 47.1 ± 9.5 52.7 ± 9.3
LPS 33.4 ± 5.5 46.7 ± 8.9
TNF-α 51.7 ± 11.4 60.7 ± 10.6
IL-8 release
PBS 23.7 ± 5.3 14.7 ± 2.8
fMLP 115 ± 19 161 ± 20
LPS 1100 ± 115 1180 ± 67
TNF-α 728 ± 81 898 ± 76
IL-1RA release
PBS 187 ± 43 229 ± 44
fMLP 178 ± 43 248 ± 42
LPS 253 ± 52 357 ± 54
TNF-α 457 ± 66 515 ± 55
CAV: Cardiac allograft vasculopathy; VEGF: Vascular endothelial growth factor;
IL: Interleukin; RA: Receptor antagonist; PBS: Vehicule; fMLP: N-formyl-Met-Leu-
Phe; LPS: Bacterial lipopolysaccharides; TNF: Tumor necrosis factor. Variables are
expressed as mean ± SEM and percentages.Discussion
In this clinical investigation, we report a decrease in cir-
culating levels of VEGF-A165 but no significant changes
in plasma levels of the proinflammatory cytokine IL-8
and the anti-inflammatory cytokine IL-1RA in stable
long-term CTx recipients. Isolated neutrophils from
CTx patients yielded a marked attenuation in the release
of VEGF-A165, IL-1RA and IL-8 in response to most ag-
onists. Although basal and stimulated levels of VEGF-
A165 were consistently lower in patients with CAV, this
difference did not reach statistical significance.
VEGF superfamily members play a pivotal role on
angiogenesis and inflammation helping to maintain
healthy adult vascular function and homeostasis [32,33].
However, VEGF analogs (predominantly VEGF-A165) also
possess significant proinflammatory properties, by their
capacity to increase vascular permeability and to promote
the adhesion and transvascular migration of leukocytes
[34,35]. There has been little data on the characterisation
and on the role of VEGF analogs following CTx. Earlier
work from Torry et al. showed that cardiac immunreactiv-
ity against VEGF-A isoforms increased significantly (pre-
dominantly VEGF-A165 isoform) in cardiac allograft
concomitantly with fibrin depositions as well as the pres-
ence of macrophages and neutrophils [17]. Recently,
Gramley and coworkers reported a significant increase in
cardiac fibrosis over time in specimens of endomyocardial
biopsies [16]. Using an immunohistochemistry approach
(selective antibody for VEGF-A isoforms), this group re-
ported a parallel increase in cardiac VEGF-A in these bi-
opsy specimens. This investigation suggested that
myocardial hypoxia occurs in long-term CTx recipients
and that VEGF-A may provide an adaptive mechanism to
reduce hypoxic stress following CTx.
Herein we report a decrease in circulating VEGF-A165
and a marked attenuation in the capacity of neutrophils
to release VEGF-A165. This contrasts with the finding
from Daly et al. [18] who reported an increase in circu-
lating levels of VEGF-C and VEGF-A165 in patients with
CAV. The reasons for these discrepancies with our data
Figure 2 Neutrophil mediated release of VEGF-A165, IL-1RA, and IL-8 in response to various agonists. healthy controls; cardiac transplant recipients
(CTx). fMLP (10−7 M); LPS (1 μg/mL); TNF-α (10 ng/mL). Data are presented as mean ± SEM. *p < 0.05; ***p < 0.001 compared to PBS-treated neutrophils.
†††p < 0.001 vs healthy controls.
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data from cardiac transplant recipients were not com-
pared with those from healthy control subjects and
about 80% of patients were treated with cyclosporine-
based immunoprophylaxis. In addition about 1/3 of pa-
tients received mycophenolate acid-based treatments.
However, one might speculate that an increase in cardiac
(cardiomyocytes) VEGF-A isoforms may be associated
with a decrease in circulating level because of the avidity
of the injured myocardium to VEGF. The decreased re-
lease of VEGF-A165 by stimulated neutrophils may also
be related to some “exhaustion” of the neutrophils re-
lated to an increased demand and/or the inhibition of
corresponding synthesis mediated by the immunosup-
pressors [36-38]. Interestingly, circulating levels of IL-8
were not significantly decreased in patients suggesting
that chronic immunosuppression may not solely explain
these observations. Our data would be in agreement
with Spisani et al. reporting no significant impacts of
cyclosporine A on either basal or agonist-stimulated
neutrophils intracellular calcium concentrations [36].
The mechanisms for these observations and the physio-
logical impacts of a decrease in VEGF-A165 in these
high-risk patients deserve further investigations.
In this study we observed no significant decrease in
plasma levels of IL-1RA and IL-8 in CTx patients com-
pared with the HC subjects. In contrast, the capacity of
stimulated neutrophils to increase the release of these
cytokines was significantly attenuated following CTx.
Various cytokines including IL-1, IL-6 and IL-8 play a
significant role on vascular injury and inflammation
[22,39]. IL-1 and TNF-α are known to induce the release
of IL-8 [22], the latter promoting the migration of neu-
trophils to the inflammatory site. IL-8 played a signifi-
cant role on ocular inflammation and angiogenesis in
conjunctiva [30] and on atherogenesis [22,40] and its in-
hibition using a specific [22] antibody reduced ischemia
reperfusion injuries in the heart [41]. IL-1RA belongs tothe IL-1 family and binds to IL-1 receptors, thereby
antagonising the inflammatory effects of IL-1α and –ß
[42]. Immune cells such as neutrophils, can secrete IL-
1RA [43,44] and the latter may prevent the proinflam-
matory effects of IL-1 [42]. The balance between IL-1
and IL-1RA systemically or locally plays an important
role in many diseases such as arthritis, renal failure, and
cancer [42,45-47]. In early post renal transplant patients,
reduced IL-1RA is associated with delayed graft function
[48] and IL-1RA gene transfer inhibits graft rejection in
an experimental model of corneal transplantation [49].
In addition, low post-transplantation IL-1RA levels cor-
relate with engraftment syndrome after autologous stem
cells transplantation in plasma cell neoplasms [50]. Basal
and stimulated IL-1RA levels had not been investigated
following CTx.
Recently, published work from our group reported a
plasmatic increase of various cytokines including IL-1
and IL-6 within the first 12 weeks following de novo car-
diac transplantation [1]. Plasma levels for these specific
cytokines decreased significantly but did not reach levels
observed in healthy control subjects at 12 months. We
also reported some elevation of plasminogen activator
inhibitor-1 (PAI-1), fibrinogen, and high sensitivity C-
reactive protein (hsCRP) in long-term CTx recipients
[2]. Levels for these specific markers were only mildly el-
evated and cytokines were not measured in these pa-
tients. Unfortunately VEGF was not measured in these
studies. In the present investigation, we expanded these
latter observations in CTx recipients by reporting min-
imal changes in basal levels of two potentially physiolo-
gically relevant cytokines. In contrast, we observed a
profound decrease in the release of VEGF-A165 along
with these two cytokines by stimulated neutrophils. The
mechanisms inducing the decrease in both IL-8 and IL-
1RA remain unknown. However, we may speculate that
a chronic state of inflammation may contribute to
decrease the potential release of inflammatory markers
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with other cytokines such as TNF-α in heart failure [51].
The attenuations in IL-1RA release may also suggest
that these patients may fail to compensate for an eleva-
tion in many proinflammatory cytokines. To what extent
these findings are related to chronic immunosuppression
or other abnormalities in cytokine regulation is a matter
for future investigations.Study limitations
This clinical investigation reported novel and significant
findings on VEGF-A165 and on selected cytokines in
CTx recipients. Only VEGF-A165 was measured. Also
the investigations of all VEGF subsets such as VEGF-A
and -C would have provided more complete data and in-
sights in these patients. It is to mention that the neutro-
phils do not have the capacity to release IL-1ß following
a proinflammatory stimulation (including LPS treatment;
0–24 hours stimulation period); even though there is an
increase in IL-1ß synthesis [27]. In addition, the detec-
tion of IL-1ß in the serum and plasma of healthy volun-
teers, using a high-sensitivity IL-1ß ELISA kit is either
non-detectable or minimally detectable in only 9 to 25%
of the measured samples. Thus, we did not measure IL-
1ß and as such the ratio of IL-1ß/IL-1RA could not be
reported and discussed. More extensive work on other
cells playing a significant role on vascular biology such
as the monocyte and lymphocyte will be justified in
future investigations. In contrast to healthy controls,
cardiac transplant patients exhibited a high prevalence
of hypertension, dyslipidemia and some degree of renal
failure. In addition all transplant recipients were on vari-
ous immunosuppressive regimen and most of them were
on antihypertensive drugs and on statins. It is likely that
these medical conditions and drug used may have played
a role on neutrophil responses. Nevertheless this poten-
tial bias could not be avoided in this clinical investiga-
tion. Also despite adequate age-matching our study
population were not sex-matched. The impact of gender
on these parameters would be a matter for future
works. In this study, patients with CAV exhibited lower
but non-significant values for all markers in response
to simulation. However, from all 18 patients, only a
small group of our study population exhibited some
mild degree of CAV. As such our report does not
allow us to conclude about the impact of CAV on these
findings.
In conclusion, CTx recipients exhibit a marked reduc-
tion in circulating VEGF-A165 as well as in neutrophil
mediated release in VEGF-A165. The mechanisms and
physiologic impacts of these findings and their relation-
ship with various severity of CAV deserve additional
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